The Indian Journal of Pediatrics

, Volume 68, Issue 5, pp 427–431 | Cite as

Pharmacotherapy of target symptoms in autistic spectrum disorders

Symphosium on Neurodevelopmental Disordes-I

Abstract

There are no aetiologically-based treatments available to cure autism. Though psychotropics have a role in the management of some symptoms of autism, clinical trial evidence for the use of psychotropics is in its infancy and needs close monitoring. About half of the subjects with high functioning pervasive developmental disorders (PDDs) are currently reported to be on psychotropics (anti-depressants, stimulants and antipsychotics), with many of them being on anti-epileptic medication simultaneously. Despite this high level of psychotropic use, few studies exist investigating the pharmacokinetics, pharmacodynamics or side-effect profiles in this population. Multiprofessional and parent partnership is essential in managing autism and psychopharmacology should be used in conjunction with environmental manipulation, educational modification and/or behavioral management strategies. A symptomatic approach to managing the difficult behaviours associated with autism is recommended. Some symptoms of autism may bemedication responsive (hyperactivity, obsessions, rituals, inattention, tics, etc), while other symptoms may beresponsive to behavioural interventions, but may require medication (aggression, anxiety, depression, impulsivity, sleep difficulties, etc), and symptoms which needspecific skill remediation are usually nonresponsive to medication (deficits in academic, social or sport domains). The new atypical antipsychotics (such as risperidone, olanzapine, amisulpiride, quetiapine) and SSRIs are increasingly being used in autism, with encouraging results, but a risk-benefit ratio of pharmacotherapy is essential with due weight being given to the sideeffects of medication. Despite symptomatic improvement with medication, one should remain cautious about longterm use of psychotropics. It is also important to recognize that psychotropics can sometimes worsen behaviour, and can produce iatrogenic symptoms. Certain anti-epileptic medication and psychotropic drugs are metabolized by the same cytochrome P450 isoenzymes in the liver. In such circumstances, the addition of a psychotropic agent may drastically alter the levels of the anti-epileptic medication and vice versa. It is suggested that specialist clinics should be involved when one is considering complex medication regimes, experimental drugs, polypharmacy, or if patients show unusual side-effects or is drug resistant.

Key words

Pharmacotherapy Medication Autism PDD Children 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Martin A, Scahill L, Klin A, Volkmar FR. Higherfunctioning pervasive developmental disorders: rates and patterns of psychotropic drug use.J Am Acad Child Adolesc Psychiatry 1999; 38 : 923–931.PubMedCrossRefGoogle Scholar
  2. 2.
    Awad GA. The use of SSRIs in young children with prevasive developmental disorders: some clinical observations.Can J Psychiatry 1996; 46 : 361–366.Google Scholar
  3. 3.
    Gingras P. Practical Paediatric Psychopharmacological prescribing in autism-the potential and the pitfalls.Autism 2000; 4: 229–249.CrossRefGoogle Scholar
  4. 4.
    Tsai LY. Psychopharmacology in autism.Phychosom Med 1999; 61: 651–665.CrossRefGoogle Scholar
  5. 5.
    Santosh PJ, Baird G. Psychopharmacotherapy in children and adults with intellectual disability.Lancet 1999; 354:231–240.CrossRefGoogle Scholar
  6. 6.
    McDougle CJ, Scahill L, McCracken JT, Aman MGet al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.Child and Adolescent Psychiatric Clinics of North America 2000; 9 (1): 201–224.PubMedGoogle Scholar
  7. 7.
    Quintana H, Birmaher B, Stedge Det al. Use of methly phenidate in the treatment of children with autistic disorder.J Aut Devel Dis 1995; 25:283–294.CrossRefGoogle Scholar
  8. 8.
    Gordon CT, State RC, Nelosn JE, Hamburger SD, Rapoport JL. A double blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder.Arch Gen Psychiatry 1993; 50:441–147.PubMedGoogle Scholar
  9. 9.
    Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder.J Clin Psychopharmacol 1992; 12:322–327.PubMedCrossRefGoogle Scholar
  10. 10.
    Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.J Clin Psychiatry 1992; 53: 77–32.PubMedGoogle Scholar
  11. 11.
    McDougle CJ, Naylor RN, Cohen DJet al. A doubleblind placebo-controlled study of fluvoxamine in adults with autistic disorder.Arch Gen Psychiatry 1996; 53: 1001–08.Google Scholar
  12. 12.
    McDougle CJ, Holmes JP, Carlson DCet al. A doubleblind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.Arch Gen Psychiatry 1998; 55:633–641.PubMedCrossRefGoogle Scholar
  13. 13.
    Horvath K, Stefanatos G, Sokolski KN, Wachtel Ret al. Improved social and language skills after secretin administration with autistic spectrum disorders.J Assoc Acad Minor Phy 1998; 9: 9–15.Google Scholar
  14. 14.
    Chez MG, Buchanan CP, Bagan BT, Hammer MSet al. Secretin and autism: a two-part clinical investigation.J Autism Dev Disord 2000; 30 : 87–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Sandier AD, Sutton KA, De Weese Jet al. Lack of benefit of a single dose of synthetic human secetin of autism and pervasive developmental disorder.NEJM 1999; 341:1801–1806.CrossRefGoogle Scholar
  16. 16.
    DeLong GR, Teage LA, Karman MM. Effects of fluoxetine treatment in young children with idiopathic autism.Dev Med Child Neurology 40 :551–562.Google Scholar
  17. 17.
    Insel RT, O’Brien DJ, Leckman JF. Oxytocin, casopression, and autism: is there a connection?Biol Psychiatry 1999; 45:145–157.PubMedCrossRefGoogle Scholar
  18. 18.
    Linday LA. Oral famotidine: a potential treatment for children with autism.Medical Hypotheses 1997; 48 (5) : 381–386.PubMedCrossRefGoogle Scholar
  19. 19.
    Carlsson ML. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamateserotonin interactions for pharmacotherapy.J Neural Transm (Budapest) 1998; 105 (4-5) : 525–535.CrossRefGoogle Scholar
  20. 20.
    DelGiudice-Asch G, Simon L, Schemeidler J, CunninghamRundles C, Hollander E. Brief Report: A pilot open clinical trial of intravenous immunoglobulin in childhood autism.J Autism Dev Disorders 1999; 29 : 157–160.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2001

Authors and Affiliations

  1. 1.Department of Chlid & Adolescent PsychiatryInstitute of PsychiatryLondonUK
  2. 2.Newcomen CentreGuy’s and St Thomas’ Hospital TrustLondon

Personalised recommendations